

1 Vaccination and three non-pharmaceutical interventions 2 determine the end of COVID-19 at 381 metropolitan statis- 3 tical areas in the US

4 Lu Zhong,¹ Mamadou Diagne,^{1*} Qi Wang,² Jianxi Gao^{3,4*}

5 ¹*Department of Mechanical, Aerospace, and Nuclear Engineering, Rensselaer Polytechnic Insti-
6 tute, Troy, NY 12180*

7 ²*Department of Civil and Environmental Engineering, Northeastern University, Boston, MA 02115*

8 ³*Department of Computer Science, Rensselaer Polytechnic Institute, Troy, NY 12180*

9 ⁴*Network Science and Technology Center, Rensselaer Polytechnic Institute, Troy, NY 12180*

10 **The rapid rollout of the COVID-19 vaccine global raises the question of whether and when**
11 **the ongoing pandemic could be eliminated with vaccination and non-pharmaceutical inter-**
12 **ventions (NPIs). Despite advances in the impact of NPIs and the conceptual belief that NPIs**
13 **and vaccination control COVID-19 infections, we lack evidence to employ control theory in**
14 **real-world social human dynamics in the context of disease spreading. We bridge the gap**
15 **by developing a new analytical framework that treats COVID-19 as a feedback control sys-**
16 **tem with the NPIs and vaccination as the controllers and a computational and mathematical**
17 **model that maps human social behaviors to input signals. This approach enables us to ef-**
18 **fectively predict the epidemic spreading in 381 Metropolitan statistical areas (MSAs) in the**
19 **US by learning our model parameters utilizing the time series NPIs (i.e., the stay-at-home**
20 **order, face-mask wearing, and testing) data. This model allows us to optimally identify three**
21 **NPIs to predict infections actually in 381 MSAs and avoid overfitting. Our numerical results**
22 **universally demonstrate our approach's excellent predictive power with $R^2 > 0.9$ of all the**
23 **MSAs regardless of their sizes, locations, and demographic status. Our methodology allows**
24 **us to estimate the needed vaccine coverage and NPIs for achieving R_e to the manageable level**
25 **and the required days for disease elimination at each location. Our analytical results provide**
26 **insights into the debates on the aims for eliminating COVID-19. NPIs, if tailored to the**

27 **MSAs, can drive the pandemic to an easily containable level and suppress future recurrences**
28 **of epidemic cycles.**

29 The ongoing global pandemic of coronavirus disease 2019 (COVID-19) has caused devastat-
30 ing loss of human lives and inflicted severe economic burden in the US¹. By 20 March 2021, more
31 than 510,000 people were killed by COVID-19, the unemployment reaches 11.5%², and fiscal
32 shortfall reaches over 200 billion³. In response to the disease, federal, state, and local governments
33 have implemented non-pharmaceutical interventions (NPIs) from encouragement and recommen-
34 dations to full-on regulation and sanctions⁴⁻⁶ and pharmaceutical interventions (PIs) with avail-
35 able vaccinations^{7,8} and drugs⁹. However, these NPIs (e.g., social distancing, face mask-wearing,
36 hand hygiene, testing, contact tracing, isolation, etc.) are often loosened and re-tightened with-
37 out rigorous empirical evidence. Methodologies, from randomized controlled trials⁵, econometric
38 methods^{10,11} to mathematical models¹²⁻¹⁸, have been developed to measure the effects of these
39 NPIs. But many of the methodologies cannot be used without predicting the pandemic when the
40 NPIs are adjusted. Besides, different sets of NPIs enforced in different places at different times
41 often come with different effects^{10,16}. Without considering NPIs' varieties on space, timing, and
42 duration, we cannot understand whether these NPIs have had the desired effect of controlling the
43 epidemic. In this study, we aim to tackle the challenge by modeling the COVID-19 spreading as
44 a feedback control system, where the NPIs and vaccination note the controllers, and then to help
45 policymakers determine the magnitude and timing of interventions' deployment as circumstances
46 change.

47 Engineering perspectives are useful in epidemic modeling¹⁹, including the principle of con-
48 trol theory that provides a theoretical basis for NPIs' functioning and transmission management.
49 Control theory, originally developed for engineered systems with applications to power grids, man-
50 ufacture, aircraft, satellite, and robots, has recently been adapted to understand the controllability
51 of complex systems emerging in ecology, biology, and society. The recent work about network
52 control enables us to identify the minimal driver nodes²⁰ or lowest control costs^{19,21} for node con-
53 trol, edge control²², target control²³, multilayer control^{24,25}, temporal control²⁶, and data-driven

54 control²⁷. However, we continue to lack general answers to practically applying control theory
55 to human and natural systems, like the dynamical system for disease spreading. The difficulty is
56 rooted in the fact that we know the pedals and the steering wheel are the drivers prompting a car
57 to move with the desired speed and in the desired direction, but the practical drivers are unknown
58 for complex human and natural systems^{28,29}. Specifically, when focusing on the COVID-19 pan-
59 demic, we hypothesize that non-pharmaceutical and pharmaceutical interventions are the "drivers"
60 to determine the dynamics of the COVID-19 pandemic in each location through controlling the
61 infection, recovery, and death rates²⁹. We validate this hypothesis by developing a parsimonious
62 model that excellently predicts how the interventions influence the spreads in 381 MSAs in the US
63 and ultimately estimates the end of COVID-19.

64 Results

65 **Model COVID-19 spreading as a feedback control system.** Increasing evidence shows that
66 the spread of COVID-19 follows compartmental models^{10,12,30-32}, such as the SIRD (Susceptible-
67 Infectious-Recovered-Death) model, which is mathematically described by the nonlinear equations
68 expressing a population balance as follows³³:

$$\begin{aligned}\dot{S} &= \mu(S(t) + I(t) + R(t)) - \beta S(t)I(t) - \mu S(t) - V, \\ \dot{I} &= \beta S(t)I(t) - \gamma I(t) - \delta I(t) - \mu I(t), \\ \dot{R} &= \gamma I(t) - \mu R(t), \\ \dot{D} &= \delta I(t),\end{aligned}\tag{1}$$

69 where S , I , R , and D are the susceptible, infected, recovered and death numbers, respectively.
70 $S + I + R + D = \Omega$ and Ω is the population at the given place. V is the ratio of people full
71 vaccinated with efficacy rate 90%³⁴. The parameter μ is the crude birth and death rate, and epi-
72 demiological parameters β , γ , and δ are the infection, recovery and death rates ($\Theta = [\beta, \gamma, \delta]^T$).
73 Studies show that epidemiological parameter are time-dependent, which adapt accordingly to the
74 change of interventions^{12,13}. By defining β_0 , γ_0 , and δ_0 as the infection, recovery and death rates
75 before interventions are imposed ($\Theta_0 = [\beta_0, \gamma_0, \delta_0]^T$), we define $\Theta(t) = \Theta_0 + U_\Theta(t)$, where

76 $U_{\Theta}(t) = [U_{\beta}(t), U_{\gamma}(t), U_{\delta}(t)]^T$ is a vector of the control input signals. As shown in Fig. 1a, the
77 controllers $U_{\Theta}(t)$ work as the edge control²² and the vaccination V works as the node control²⁰.
78 Based on nonlinear feedback control law, we develop the controllers $U_{\Theta}(t)$ using the feedback lin-
79 earization approach. Then the SIRD model could perfectly track the reference trajectories which
80 is generated from reported real-world pandemic data. As illustrated in Fig. 1b, the output model
81 trajectory fits the real-world 3-dimensional data when the time-varying controllers are included,
82 while it fails to fit when the controllers are not considered. Note that our approach is general and
83 can be extended to other models that consider n -dimensional data.

84 Next, we propose the parsimonious model by employing the *difference-in-difference* esti-
85 mation, which maps human behavior toward NPIs into the designed controller, as shown in Fig.
86 1c. This method enables us to measure the effect of NPIs on the controllers U_{Θ} by comparing the
87 infection dynamics before and after the same region's NPIs deployment. Beyond existing models,
88 which assume the effects on policies are approximately linear¹⁰, we also identify the interactions
89 between policies. Thus, we are able to compile the evolution of human behaviour toward the
90 NPIs, $\theta_I = [\theta_s, \theta_f, \theta_g]^T$, (e.g., stay-at-home order θ_s , face-mask wearing θ_f , and testing θ_g) to the
91 evolution of the control signals with their respective effects, $\mathbf{W}_{\Theta}^I = [w_{\Theta}^s, w_{\Theta}^f, w_{\Theta}^g]^T$.

92 In short, our two-steps approach captures how the NPIs and vaccinations govern the disease
93 dynamics, through combining the principles of control theory^{29,35} and statistical estimation^{10,36}.

94 **Tracking the pandemic's trajectory with designed controllers.** To validate its accuracy in pre-
95 dicting the disease evolution in the future and its applicability in determining the needed interven-
96 tions to control the infection process, we test the NPIs data and infection data at 381 Metropolitan
97 statistical areas (MSAs) from 1 April 2020 to 20 February 2021. The MSAs, defined as the core
98 areas integrating social and economic adjacent counties, is contiguous areas of relatively high pop-
99 ulation and traffic density. We consider each MSA as a "closed population" the disease evolution

100 could be modeled by the nonlinear SIRD dynamical model, Eq. (1), in a compact form, as

$$\dot{X} = F(X, U_{\Theta} + \Theta_0), \quad (2)$$

101 with $X = [S, I, R, D]^T$ is the state/output vector and $U_{\Theta} = [U_{\beta}, U_{\gamma}, U_{\delta}]^T$ is the input vector.
102 Using feedback linearization control design, we construct a nonlinear feedback control law $U_{\Theta} =$
103 $\phi(X, \dot{X}, X_d, \dot{X}_d)$, to track the real-world pandemic trajectories $X_d = [S_d, I_d, R_d, D_d]^T$ (see Eqs.
104 (6-11) in Methods). The feedback law $\phi(\cdot)$ relies on the measurements of the model full state X
105 and the reference trajectory (X_d) and their time derivative (\dot{X} and \dot{X}_d).

106 Theoretically, for each MSA, the output trajectory X perfectly fits the reported infection
107 trajectory X_d when the control action U_{Θ} is applied. This fact is illustrated in Fig. 2, which shows
108 the evolution of the predicted and reported trajectories from 1 April 2020 to 20 February 2021
109 for two MSAs, namely the "New York" MSA (with New York as the core) and 'Houston' MSA
110 (with Houston as the core). Moreover, the excellent alignments between the real-world and model
111 data of all 381 MSAs indicate our approach's predictive power, as shown in Fig. 2b. On the other
112 side, Fig. 2c shows all MSAs' infection rate $[\beta_0 + U_{\beta}(t)]$, recovery rate $[\gamma_0 + U_{\gamma}(t)]$, and death
113 rate $[\delta + U_{\delta}(t)]$, respectively, and mark out the respective rates for the two examples of MSA.
114 Overall speaking, the infection rate and recovery rate decrease till May, rebound in June, decrease
115 again to the lowest in September and start to fluctuate till February. The death rate continues to
116 decrease in October and stays relatively constant beyond. As validated in literature⁴, "New York"
117 MSA enforces interventions more effectively and earlier, leading to a relatively lower infection
118 rate, recovery rate, and death rate than most MSAs till October. One can observe that "Houston"
119 MSA follows medium patterns.

120 Having the daily transmission rate, recovery rate, and death rate, we compute the effective
121 reproductive ratio $R_e(t) = \frac{[\beta_0 + U_{\beta}(t)]S(t)}{[\gamma_0 + U_{\gamma}(t)] + [\delta_0 + U_{\delta}(t)] + \mu}$, representing the expected number of secondary
122 infected cases at time t when no vaccinations are rolled out. The function $R_e(t)$ is a critical thresh-
123 old in understanding whether the outbreak is under control. More precisely, if $R_e(t) < 1$, then the
124 ongoing outbreak will eventually fade out, whereas $R_e(t) > 1$ means an acceleration of the infec-

125 tion dynamics leading to a substantial growth of infected cases and deaths. Fig. 2d-e respectively
 126 visualize the temporal and spatial distribution of the MSAs' effective reproductive ratio. Our re-
 127 sults reveal that just a few MSAs' effective reproductive ratios ever reach $R_e(t) < 1$, implying the
 128 need to implement more rigorous interventions to achieve an effective controlling of the pandemic.
 129 For example, from 14 February 2021 to 20 February 2021, the average effective reproductive ratios
 130 in "New York" and "Houston" MSAs are evaluated as 1.468 and 1.393, respectively, revealing a
 131 critical need for stronger interventions.

132 **Mapping human behaviours as actuators to steer NPIs as controllers.** Although our con-
 133 troller, U_Θ , precisely predicts the infectious, death toll, and recovery, it is thus far unknown how
 134 the measurable interventions change the controllers. Compared with the driving car, it is similar
 135 that we know the desired speed and direction in order to move the car to the target location, but we
 136 do not know what the pedals and the steering wheel for epidemic control are and how the changes
 137 in the pedals and the steering wheel determine the speed and direction. In another word, as depicted
 138 in Fig. 1, we assume that the changes of interventions, directly steering the control signals, will
 139 shape the disease dynamics when they are tightened and loosen to different levels. For multiple
 140 NPIs θ_I , we divide them into two sets, i.e., the set of community NPIs ϑ^c (e.g., social distancing
 141 and quarantine) and the set personal NPIs ϑ^p (e.g., face covering, test, and frequent hand wash).
 142 Then we develop the following mathematical model $\hat{U}_\Theta(t) = [U_\beta, U_\gamma, U_\delta]^T = f(\theta_I(t), \mathbf{W}_\Theta^I)$ as
 143 (see [Eqs. (12-15)] in Methods)

$$\hat{U}_\Theta(t) = \prod_{i \in \{c,p\}} (1 - \sum_{j \in \vartheta^i} w_\Theta^j \theta_j(t)) - 1 \quad (3)$$

144 where $\hat{U}_\Theta(t)$ is the estimate of the control action based on NPIs with their magnitudes $\theta_j(t)$ and
 145 their impact value w_Θ^j . For a the specific NPI j , large w_Θ^j value demonstrates that NPI j has strong
 146 impact. If $w_\Theta^j = 0$, the control $\hat{U}_\Theta(t)$ is independent with the NPI j . The term $\prod_{i \in \{c,p\}}$ indicates
 147 that community NPIs ϑ^c and personal NPIs ϑ^p have a joint affect on the controller. For either
 148 community NPIs ϑ^c or personal NPIs ϑ^p , $1 - \sum_{\theta_j \in \vartheta^i} w_\Theta^j \theta_j(t)$ term denotes the combined impact
 149 of the NPI set. Usually, \hat{U}_Θ is a non-positive value, showing the reductions in each controller.

150 Given the collected data sets for eight NPIs, we evaluate the goodness of fit versus different
151 combinations of NPIs to find an effective parsimonious model for Eq. 3. A parsimonious model,
152 which has great explanatory predictive power, accomplishes a better prediction of controllers as
153 few NPIs as possible. With 70% of the dataset of NPIs as the training data, we use the mean
154 absolute error to test the predictive accuracy for the rest 30% of the dataset. Fig. 3 shows that
155 including three NPIs in the model gains the highest predictive accuracy for the designed controllers
156 (see supplementary text for the details). We find that the most representative NPIs for Eq. 3
157 are: (1) stay-at-home order, represented by the normalized ratio of excessive time of staying at
158 home, θ_s ; (2) face-mask wearing, represented by the fraction of people wearing face masks, θ_f ;
159 (3) testing, represented by the normalized fraction of tested population, θ_g . Commonly, stay-at-
160 home order and face-mask wearing have a positive impact on decreasing the number of reported
161 cases. Differently, testing $\theta_g(t)$ may positively or negatively impact the reported infected cases.
162 The reason is that more testing could allow identifying more cases when the number of testing is
163 not sufficient, and yet, more testing may also lead to less infected cases⁶. Representing the three
164 NPIs as $\boldsymbol{\theta}_I = [\theta_s, \theta_f, \theta_g]$, then,

$$\hat{U}_\Theta(t) = (1 - w_\Theta^s \theta_s(t)) \left(1 - w_\Theta^f \theta_f(t) - w_\Theta^g \theta_g(t) \right) - 1 \quad (4)$$

165 In the following studies, we only use these three selected NPIs for predictions.

166 **Effects of NPIs on shaping the disease dynamics.** Based of the parsimonious model of Eq. (4),
167 we learn the parameter-by-intervention specific marginal effects w_Θ^s , w_Θ^f , and w_Θ^g , reflecting the
168 variations of \hat{U}_Θ as a function of the evolution of the time-dependent local NPIs $\theta_s(t)$, $\theta_f(t)$, and
169 $\theta_g(t)$ at MSAs. With the objective to directly infer the \hat{U}_Θ with the NPIs data, we first use 70%
170 dataset of NPIs as the training data to learn the marginal effects. Then, we estimate the counterparts
171 \hat{U}_Θ given as Eq. (4) using the 30% left testing datasets and evaluate the fit between U_Θ and \hat{U}_Θ .
172 Taking the "New York" MSA and "Houston" MSA shown in Fig. 4a-b as illustrative examples;
173 given the evolution of NPIs, the estimated control signals \hat{U}_β and \hat{U}_δ with the learned marginal
174 effects, fit the predicted model-based control law defined in terms of U_β and U_δ . Based on the

175 proportionality between $U_\gamma(t)$ and $U_\beta(t)$ (see Fig. S2), i.e., $U_\beta(t)/U_\gamma(t) = 2.664$, here, we only
176 consider $U_\beta(t)$ and $U_\delta(t)$.

177 It is remarkable that for all MSAs, Eq. (4) stays robust to the huge heterogeneity of locality.
178 As depicted in Fig. 4c, the NPIs have a great high standard deviation (σ) across MSAs, especially
179 for stay-at-home order and face-mask wearing. One can notice that the average magnitude of stay-
180 at-home order decreases from 80% to 40% recently with $\sigma = 0.140$. Besides, nearly 53.56% of
181 people are wearing face masks when being outdoors with $\sigma = 0.20$ while the average magnitude
182 of testing increases to 9.19% with $\sigma = 0.032$. To test the robustness of the model of Eq. (4), we
183 trained and validated the model iteratively on different MSAs' datasets for NPIs. The distributions
184 of marginal effects across the three NPIs are shown in Fig. 4d. Most MSAs' marginal effects for
185 stay-at-home order and face-mask wearing are negative. The statistics imply the generic feature of
186 the Eq. (4) in capturing NPIs' effects despite the huge regional heterogeneity of human behaviours.
187 However, the average marginal effect of testing has two opposite outcomes. For $\hat{U}_\beta(t)$, 73.5% of
188 MSAs' testing' marginal effects are positive, meaning 26.5% of them are negative. For $\hat{U}_\delta(t)$,
189 46.0% of MSAs' testing' marginal effects are positive, meaning 54.0% of them are negative. The
190 positive effects suggest that testing is favorable to finding more infections and deaths, while the
191 negative effects show that testing reduces infection or death.

192 Applying the estimated control signals $\hat{U}_\beta(t)$, $\hat{U}_\delta(t)$, and $\hat{U}_\gamma(t) = \hat{U}_\beta(t)/2.264$ to the SIRD
193 model, we find that the new output trajectories \hat{X} fit the reported infection X_d with $R^2 \geq 0.9$,
194 as show in Fig. S3. As well, Fig. 4e-f depict the predicted infected/dead cases with reported
195 infected/dead cases on 20 October 2020 and 20 February 2021. All the results further validate the
196 model in assessing NPIs' effects on disease dynamics.

197 **Needed NPIs and vaccinations for achieving R_e to manageable level.** The two-steps approach,
198 integrating the designed controllers in Eqs. (1-2) and the effect of NPIs on controllers in Eqs. 4,
199 has successfully mapped human behaviors to NPIs to infection rate, recovery rate, and death rate

200 of the SIRD model. Then, the effective reproductive number R_e can be equivalently translated in
201 terms of magnitudes of NPIs (θ_I) and V (the ratio of people full vaccinated with efficacy rate 90%
202 ³⁴), that is,

$$R_e(t) = \frac{\beta_0 + f(\theta_I, \mathbf{W}_\beta^I)}{\gamma_0 + \delta_0 + \mu + f(\theta_I, \mathbf{W}_\gamma^I) + f(\theta_I, \mathbf{W}_\delta^I)}(S(t) - V). \quad (5)$$

203 From the equation above, we can determine the needed magnitude of NPIs for achieving $R_e(t) < 1$,
204 criteria for the disease die out, under a given vaccination coverage. Here, the vaccination coverage
205 is viewed as an open-loop control action or a given parameter whose assigned value affects the
206 speed of propagation of the disease.

207 When there is no vaccination administered in the US (like before 12 January 2021 $V = 0$),
208 the needed magnitude of NPIs to achieve an effective reproductive number below the threshold,
209 $R_e(t) < 1$ ³⁷, for 'New York' and 'Houston' MSAs are shown in Fig. 5a-b. The "triangular
210 prism" in three dimensions represents the needed magnitude of the stay-at-home order, face-mask
211 wearing, and testing. The horizontal slices of the "triangular prism" are the visualization for the
212 needed magnitude of stay-at-home order and face-mask wearing if the magnitude of testing is
213 fixed. If stay-at-home order and face-mask wearing interventions are enforced at a level greater
214 than about 80%, $R_e(t) < 1$, which forms a "triangle" as shown in Fig. 5a-b. As opposed to stay-at-
215 home order and face-mask wearing, the testing intervention has a positive marginal effect on 'New
216 York' MSA and 'Houston' MSA. Hence, in both cases, the "triangle" becomes smaller for larger
217 testing. Some MSAs ('Log Angles' MSA and 'Miami' MSA in Fig. S4) have a negative marginal
218 effect for testing intervention, and their "triangle" becomes bigger for larger testing. According to
219 their testing interventions' marginal effects, the shapes of "triangular prism" for more MSAs are
220 shown in Fig. S4.

221 Since 12 January 2021, the US began the first jab of vaccine, and undoubtedly, $R_e(t)$ could
222 be smaller with mass vaccinations according to the Eq. (5). For different ratios of fully vaccinated
223 people with 90% efficiency, we could find at least how much NPIs could be relaxed (reduced) to
224 achieve $R_e(t) = 1$ in Fig. 5c. Setting aside testing intervention, more magnitude of stay-at-home
225 order and face-mask wearing interventions could be eased if more people are fully vaccinated.

226 However, when 60% of people are fully vaccinated, only 55.3% of stay-at-home order and 64.8%
227 face-mask wearing could be eased. When 70% people are fully vaccinated, the stay-at-home order
228 and face-mask wearing could be eased entirely. However, to achieve $R_e(t) < 1$, the policymakers
229 should relax NPIs with more cautions.

230 **Needed days of eliminating the pandemic locally with vaccinations.** Moreover, due to the
231 unknowns around mutations in escalating the disease's infectiousness³⁸ and human's long-term
232 immunity to the disease³⁹, suppressing the disease to an acceptable level with NPIs but not aim-
233 ing to eliminate it could make COVID-19 an endemic^{40,41}. A COVID endemic could claim mil-
234 lions of more lives each year and cause devastating economic burdens on immunization, treat-
235 ment, and prevention. Also, repeated tightening and loosening interventions due to recurrent
236 outbreaks, without a doubt, increase the difficulty to decide the right moment of enforcing exit
237 strategies^{14,35,42,43}. Currently, three vaccines are authorized and recommended in the United States
238 from Pfizer-BioNTech, Moderna, and Johnson & Johnson. By 10 March, more than 37.4 million
239 adults in the U.S. have been fully vaccinated⁴⁴. Despite continued efforts of NPIs and vaccine roll-
240 out, the plateaued numbers of infection cases and the fast-spreading variants still pose significant
241 uncertainty about whether "zero COVID" could be achieved locally in the US. Given the examples
242 of New Zealand⁴⁵, Vietnam, Brunei, and Island states in the Caribbean⁴⁰, which ever reached a
243 "Zero COVID" stage, we investigate the possibility of reaching zero contamination in the MSAs.
244 We refer to "Zero COVID" to describe a situation that leads to no new cases at least for three
245 months in a given location, referring to literature⁴⁶. Furthermore, the day when the following three
246 months having zero new cases is defined as the elimination day.

247 We assume that the ratio of fully vaccinated people (also call vaccination coverage), follows
248 the innovation adoption model according to Rogers⁴⁷, which is a normal distribution, $H(t)$, see Eq.
249 (16)-(17). Then, the total number of immunized people is defined as $V(t) = aH(t)$ where a is the
250 vaccine effectiveness ($a = 90\%$). As shown in Fig. 6a, the reported data reveal that the ratio of fully
251 vaccinated people from 12 January 2021 to 20 February 2021 in the US increases to 5.40%. By

252 fitting the real-world ratio, we obtained the vaccination coverage as a curve that gradually reaches
253 saturation within different periods (T_s). Considering a full vaccination of 50% of people after 360
254 days since 12 January 2021, the average elimination day for all MSAs corresponds to the hundred
255 seventieth day. Under this configuration, from in Fig. 6b, one can notice that 'New York' MSA
256 reaches a total elimination stage after 197 days while 'Houston' MSA achieves a total elimination
257 stage after 187 days. Of course, one could define a vaccination strategy rollout accounting for
258 nonuniform saturation coverage in different periods. Fig. 6c comprehensively presents all MSAs'
259 elimination days for vaccination coverage ranging from 0% to 90% with vaccination period (T_s)
260 equals to 90 days, 180 days, 270 days, and 360 days. Our results reveal that broader vaccination
261 coverage further reduces both the remoteness of the elimination day and the death toll. On the
262 other side, a larger vaccination period expands the time range needed to reach the elimination day
263 and leads to a more significant death toll. For the case in Fig. 6b, a total of 23,920,837 more people
264 would be infected, and 1,199,202 more people would be dead because of COVID-19 if 50% of peo-
265 ple are fully vaccinated in 360 days. On the contrary, if 90% of the population is fully vaccinated
266 in 360 days, the average elimination day for all MSAs is about 129 days after implementing the
267 vaccination strategy, with 20,428,296 more infected cases and 9,127,85 more dead cases overall.
268 As shown in Fig. S6-S7, "New York" MSA, 'Los angels' MSA, "Chicago" MSA, "Dallas" MSA,
269 "Phoenix" MSA, "Boston" MSA and "Philadelphia" MSA have far more death than other MSAs,
270 meaning they need stricter interventions in reducing death because of COVID-19. In summary,
271 all these results emphasize that the earlier, aggressive vaccination strategies are deployed in each
272 MSA, the earlier the pandemic could be eliminated, leaving fewer deaths from the disease.

273 **Discussion**

274 We present the COVID-19 pandemic as the feedback control system to show how the evolution
275 of disease adapt to human behaviours to NPIs and the vaccine coverage. This approach enable
276 us to model the linear and nonlinear effects of multiple NPIs on the SIRD model-based feedback
277 controllers on the epidemiological parameters. Through reducing eight NPIs to three representa-

278 tive three (i.e., stay-at-home order, face-mask wearing, and testing), we obtain the model having
279 great explanatory predictive power toward disease dynamics. By studying the NPIs at 381 MSAs
280 from 1 April 2020 to 20 February 2021, we find that the two-steps approach is robust and efficient
281 to predict daily infection and death accurately. Beyond in line with existing studies that NPIs are
282 effective in suppressing the disease outbreaks^{30,48,49}, we could directly link the NPIs' marginal
283 effects to the effective reproductive number R_e . It implies that, without the need for up-to-date
284 knowledge of current infections and 'nowcasting'. Besides accurate forecast on both case counts
285 and deaths, this approach could provide practical information for policymakers regarding the ex-
286 tent of safely relaxing NPIs and the needed vaccination coverage to end COVID-19 locally. The
287 approach is also universal and thus can be used by policymakers elsewhere.

288 Through analyzing the needed NPIs for keeping $R_e < 1$, we find that MSAs should continue
289 to enforce their stay-at-home order and face-mask wearing. Loosening the degree below 80% could
290 lead to a resurgence of COVID-19. Our results show that MSAs should continue to require wearing
291 masks and unless 60% of people are fully vaccinated, the MSA should not relax the stay-at-home
292 order and face-mask wearing intervention.

293 There is an ongoing debate on if the elimination of COVID-19 ("Zero COVID") is possible^{40,41}.
294 It is considered by some as the only way to prevent future crises and cannot be achieved without
295 mass vaccination. Using the "Zero COVID" as a guiding criterion, i.e., no new infection at least for
296 three months, we test how many days it can be achieved if 50% MSA populations are vaccinated
297 in a 360-day period. We find that, on average, it takes 170 days to reach the "Zero COVID" mile-
298 stone. It is worth noting that the promising result can be undermined by many external factors, like
299 importation cases from other areas, making the total elimination a long process with fluctuations
300 on new infections. In addition, some scientists argue pursuing the "Zero COVID" comes at a huge
301 cost to normal human life^{40,41} and can thus out-weigh the benefits. Nevertheless, our experiments
302 reinforce the argument that maintaining NPIs and encouraging people to get vaccines are necessary
303 and key strategies to lower the new infections as much as possible.

304 Our study has some limitations. The first limitation is rooted in the dataset for COVID-19
305 and the dataset for NPIs. Given the mass mild or asymptomatic infections, the inaccuracy of re-
306 ported infections and deaths would increase the uncertainty of the SIRD model-based feedback
307 controllers. The second limitation is assuming each MSA as the closed population, which ignores
308 the fluctuation of infections caused by case importation and exportation. This simplification would
309 influence the results from needed NPIs and PIs for suppressing COVID-19 to elimination test.
310 The third limitation is assuming vaccination adoption follows the curve of diffusion of innovations
311 without considering people's attitude to vaccinations. As the attitudes towards vaccination vary by
312 age, race, ethnicity, and education, it is hard to capture the full complexity. In our current work,
313 we use feedback linearization to design the control signals, and we may improve the accuracy
314 by considering other controller design strategies, for example, adaptive controller^{50,51}, model pre-
315 dictive control⁵², or intelligent control⁵³. Nevertheless, our study provides practical insights into
316 tightening or relaxing NPIs for the aim of living with COVID-19. Also, we provide the possibility
317 of achieving "Zero COVID" in metropolitan areas if vaccination is stable and efficient enough.

318 **Methods**

319 **Dataset.** *2019-COVID pandemic.* We acquire the second-administrative units' COVID-19 cases
320 from the 2019 Novel Coronavirus Visual Dashboard operated by the Johns Hopkins University
321 Center for Systems Science and Engineering⁵⁴. It covers the counties' reported infected and dead
322 cases at the US and the whole countries' infected and dead cases from 21 January 2020 to 20
323 February 2021. We integrate counties' COVID-19 cases for 381 MSAs defined by the United
324 States Office of Management and Budget (OMB), which serves as a high degree of social and
325 economic core areas.

326 *Testing Capacity.* The testing data at each county is also collected by the Johns Hopkins
327 University Center for Systems Science and Engineering⁵⁴. By integrating the counties' testing
328 data, we get each MSA's daily ratio of total testing over MSA's population.

329 *Stay-at-home Data.* Daily data about the observed minutes at home and observed minutes
330 outside of home for all devices are counted at each county by the Safegraph⁵⁵, which is a platform
331 of collecting the points of interests (POIs) from anonymous mobile devices. Integrating the data,
332 we could get each MSA's ratio of time at home, i.e, the fractions of the observed minutes at home
333 over the sum of observed minutes at home and outside home, which is reflective of people mobility
334 pattern for local governments' anti-contagious policies. By subtracting the benchmark ratio (the
335 average ratio of time at home before 13 March 2020) and then normalizing the ratios from 0 to 1,
336 we get each MSA's ratio of excessive time at home.

337 *People Wearing Face Mask.* We assume that the search of "face mask" collected by Google
338 Trend equals to the fraction of people having the awareness of wearing face masks in each MSA.
339 Combined the fractions and the weekly percentages of people wearing face mask in the US pro-
340 vided by YouGov⁵⁶, we could obtain each MSA's daily percentage of people wearing face mask.
341 We use the similar approach to collect the data of people support school closure, quarantine ,
342 working from home, frequent hand wash, and avoid crowding.

343 *Vaccination Data.* CDC provides the overall US COVID-19 Vaccine Distribution and Ad-
344 ministration, mainly for Pfizer-BioNTech and Moderna.

345 **Deriving the feedback controllers.** The feedback controllers measure the output of the SIRD
346 model and then manipulates the inputs on infection rate, recovery rate, and death rate of as needed
347 to drive the model output toward the desired COVID-19 pandemic trajectory. In another word,
348 given the controllability of the SIRD model (see supplementary text), then we could rewrite the
349 Eq. (1) as

$$\begin{aligned}\frac{dI}{dt} &= [\beta_0 + U_\beta(t)]SI - [\gamma_0 + U_\gamma(t)]I - [\delta_0 + U_\delta(t)]I - \mu I \\ \frac{dR}{dt} &= [\gamma_0 + U_\gamma(t)]I - \mu R \\ \frac{dD}{dt} &= [\delta_0 + U_\delta(t)]I\end{aligned}\tag{6}$$

350 with the controller set $U_{\Theta}(t) = [U_{\beta}, U_{\gamma}, U_{\delta}]^T$. $U_{\beta}, U_{\gamma}, U_{\delta}$ are the controllers on infection rate, re-
 351 covery rate, and death rate. For the reference COVID-19 pandemic trajectory $X_d = [S_d, I_d, R_d, D_d]^T$
 352 and its corresponding output trajectory X , the error dynamics $X_d - X$ is governed by the following
 353 equations

$$\dot{\tilde{I}}(t) = -k_1\tilde{I}(t), \quad \dot{\tilde{R}}(t) = -k_2\tilde{R}(t), \quad \dot{\tilde{D}}(t) = -k_3\tilde{D}(t), \quad (7)$$

354 where, $\tilde{I} = I_d - I$, $\tilde{R} = R_d - R$, and $\tilde{D} = D_d - D$. Here, k_1, k_2 , and k_3 are positive gains of the
 355 designed feedback controller. The solution to the linear ordinary differential equations above are
 356 expressed as

$$\tilde{I}(t) = e^{-k_1 t}\tilde{I}(0), \quad \tilde{R}(t) = e^{-k_2 t}\tilde{R}(0) \quad \tilde{D}(t) = e^{-k_3 t}\tilde{D}(0), \quad (8)$$

357 and $(\tilde{I}(t), \tilde{R}(t), \tilde{D}(t)) \rightarrow (0, 0, 0)$. Therefore, the error system is exponentially stable and
 358 $X(t) \rightarrow X_d(t)$. The simulation of the closed-loop system is performed selecting $k_1 = k_2 = k_3 =$
 359 0.1. The controllers are

$$U_{\beta}(t) = \begin{cases} \frac{1}{SI} \left(\dot{I}_d + \mu I + [\gamma_0 + U_{\gamma}(t)]I + [\delta_0 + U_{\delta}(t)]I - k_1(I_d - I) \right) - \beta_0, & \text{for } U_{\beta}(t) > -\beta_0 \\ -\beta_0, & \text{for } U_{\beta}(t) \leq -\beta_0 \end{cases} \quad (9)$$

$$U_{\gamma}(t) = \begin{cases} \frac{1}{I} \left(\dot{R}_d + \mu R - k_2(R_d - R) \right) - \gamma_0, & \text{for } U_{\gamma}(t) > -\gamma_0 \\ -\gamma_0, & \text{for } U_{\gamma}(t) \leq -\gamma_0 \end{cases} \quad (10)$$

$$U_{\delta}(t) = \begin{cases} \frac{1}{I} \left(\dot{D}_d - k_3(D_d - D) \right) - \delta_0, & \text{for } U_{\delta}(t) > -\delta_0 \\ -\delta_0, & \text{for } U_{\delta}(t) \leq -\delta_0 \end{cases} \quad (11)$$

362 To prevent un-physical negative transmission rate $U_{\beta}(t)$, recovery rate $U_{\gamma}(t)$, and death rate $U_{\delta}(t)$,
 363 the controllers are clipped such that the time-dependent epidemiological parameters are always
 364 positive. Here $\Theta_0 = [\beta_0, \gamma_0, \delta_0]^T$ is the pre-intervention epidemiological parameters learned by
 365 infection of 'New York' MSA from 1 March 2020 to 13 March 2020 with Nelder-Mead simplex
 366 algorithm⁵⁷. For the controllers, whatever the values for Θ_0 , the error system is stable and $X(t) \rightarrow$
 367 $X_d(t)$.

368 **Using difference-in-difference method to learn the NPIs' marginal effects to the controllers.**

369 For NPI set θ_I , we use the linear regression model for difference-in-difference to calculate their
 370 effects on the vector of infection rate, recovery rate, and death rate $U_\Theta(t) + \Theta_0$. Consider the
 371 model,

$$U_\Theta(t) + \Theta_0 = \lambda(t) + f(\theta_I(t)) + \epsilon_\Theta(t) \quad (12)$$

372 where $\lambda(t)$ is the facotr for time trend and $\epsilon_\Theta(t)$ is the residual term. Then, the difference of
 373 outcome controllers from time $t - 1$ to time t is

$$\begin{aligned} U_\Theta(t) - U_\Theta(t - 1) &= [\lambda(t) + f(\theta_I(t)) + \epsilon_\Theta(t)] \\ &\quad - [\lambda(t - 1) + f(\theta_I(t)) + \epsilon_\Theta(t - 1)] \end{aligned} \quad (13)$$

374 Adding up the all difference from time $t = 0$ to time t

$$\begin{aligned} U_\Theta(t) - U_\Theta(0) &= \sum_{t' \in [1, t]} \lambda(t') - \sum_{t' \in [0, t-1]} \lambda(t') + \sum_{t' \in [1, t]} \epsilon_\Theta(t') - \sum_{t' \in [0, t-1]} \epsilon_\Theta(t') \\ &\quad + f(\theta_I(t)) - f(\theta_I(0)) \\ &\approx f(\theta_I(t)) - f(\theta_I(0)) \end{aligned} \quad (14)$$

375 As when $t = 0$ no NPIs are implemented, thus, $U_\Theta(t) = 0$ and $f(\theta_I(0)) = 0$,

$$U_\Theta(t) = f(\theta_I(t), \mathbf{W}_\Theta^I) \quad (15)$$

376 **Vaccination adoption model.** Like the innovation adoption model, the daily newly vaccination
 377 adoption (vaccination coverage) will follow the bell curve, the normal distribution,

$$h(t, u, \sigma) = \hat{V} \frac{1}{\sigma \sqrt{2\pi}} e^{-\frac{1}{2} \left(\frac{t-u}{\sigma} \right)^2} \quad (16)$$

378 where \hat{V} is the saturation of vaccination coverage. The the cumulative vaccination adoption (vac-
 379 cination coverage) is

$$H(t) = Pr(1 \leq x \leq t) = \int_1^t h(t, u, \sigma) dt \quad (17)$$

380 with $t \in [1, T_s]$. It means, the cumulative vaccination coverage will reach saturation of \hat{V} in
 381 T_s days. In the test of "Zero COVID", we tune the u and σ to fit the real-world vaccination
 382 coverage in the United States from 12 January 2021 to 20 Februray 2021 for $\hat{V} \in [0.1, 0.9]$ and
 383 $T_s \in \{120, 180, 250, 360\}$ in Fig. 6.

- 385 1. Organization, W. H. Covid-19 weekly epidemiological update (2020).
384
- 386 2. Interim economic projections for 2020 and 2021. <https://www.cbo.gov/publication/56351>.
387 Accessed: 2021-02-20.
- 388 3. The Council of State Governments. Covid-19: Fiscal impact to states and strategies for recovery (2020).
389
- 390 4. Pei, S., Kandula, S. & Shaman, J. Differential effects of intervention timing on covid-19
391 spread in the united states. *Science advances* **6**, eabd6370 (2020).
- 392 5. Haushofer, J. & Metcalf, C. J. E. Which interventions work best in a pandemic? *Science* **368**,
393 1063–1065 (2020).
- 394 6. Chiu, W. A., Fischer, R. & Ndeffo-Mbah, M. L. State-level needs for social distancing and
395 contact tracing to contain covid-19 in the united states. *Nature Human Behaviour* **4**, 1080–
396 1090 (2020).
- 397 7. Le, T. T. *et al.* The covid-19 vaccine development landscape. *Nat Rev Drug Discov* **19**,
398 305–306 (2020).
- 399 8. Bubar, K. M. *et al.* Model-informed covid-19 vaccine prioritization strategies by age and
400 serostatus. *Science* (2021).
- 401 9. Rabby, M. I. I. Current drugs with potential for treatment of covid-19: a literature review.
402 *Journal of pharmacy & pharmaceutical sciences* **23**, 58–64 (2020).
- 403 10. Hsiang, S. *et al.* The effect of large-scale anti-contagion policies on the covid-19 pandemic.
404 *Nature* **584**, 262–267 (2020).
- 405 11. Cho, S.-W. Quantifying the impact of nonpharmaceutical interventions during the covid-19
406 outbreak: The case of sweden. *The Econometrics Journal* **23**, 323–344 (2020).
- 407 12. Dehning, J. *et al.* Inferring change points in the spread of covid-19 reveals the effectiveness
408 of interventions. *Science* (2020).

- 409 13. Chen, Y.-C., Lu, P.-E., Chang, C.-S. & Liu, T.-H. A time-dependent sir model for covid-19
410 with undetectable infected persons. *IEEE Transactions on Network Science and Engineering*
411 (2020).
- 412 14. Ruktanonchai, N. W. *et al.* Assessing the impact of coordinated covid-19 exit strategies across
413 europe. *Science* **369**, 1465–1470 (2020).
- 414 15. Vardavas, R. *et al.* The health and economic impacts of nonpharmaceutical interventions to
415 address covid-19. *RAND Report TLA* **173** (2020).
- 416 16. Brauner, J. M. *et al.* Inferring the effectiveness of government interventions against covid-19.
417 *Science* **371** (2021).
- 418 17. Jing, Q.-L. *et al.* Household secondary attack rate of covid-19 and associated determinants in
419 guangzhou, china: a retrospective cohort study. *The Lancet Infectious Diseases* **20**, 1141–1150
420 (2020).
- 421 18. Zhong, L., Diagne, M., Wang, W. & Gao, J. Country distancing increase reveals the effective-
422 ness of travel restrictions in stopping covid-19 transmission (2020).
- 423 19. Yan, G. *et al.* Spectrum of controlling and observing complex networks. *Nature Physics* **11**,
424 779–786 (2015).
- 425 20. Liu, Y.-Y., Slotine, J.-J. & Barabási, A.-L. Controllability of complex networks. *nature* **473**,
426 167–173 (2011).
- 427 21. Yan, G., Ren, J., Lai, Y.-C., Lai, C.-H. & Li, B. Controlling complex networks: How much
428 energy is needed? *Physical review letters* **108**, 218703 (2012).
- 429 22. Nepusz, T. & Vicsek, T. Controlling edge dynamics in complex networks. *Nature Physics* **8**,
430 568–573 (2012).
- 431 23. Gao, J., Liu, Y.-Y., D’souza, R. M. & Barabási, A.-L. Target control of complex networks.
432 *Nature communications* **5**, 1–8 (2014).

- 433 24. Pósfai, M., Gao, J., Cornelius, S. P., Barabási, A.-L. & D'Souza, R. M. Controllability of
434 multiplex, multi-time-scale networks. *Physical Review E* **94**, 032316 (2016).
- 435 25. Menichetti, G., Dall'Asta, L. & Bianconi, G. Control of multilayer networks. *Scientific reports*
436 **6**, 1–8 (2016).
- 437 26. Li, A., Cornelius, S. P., Liu, Y.-Y., Wang, L. & Barabási, A.-L. The fundamental advantages
438 of temporal networks. *Science* **358**, 1042–1046 (2017).
- 439 27. Baggio, G., Bassett, D. S. & Pasqualetti, F. Data-driven control of complex networks. *Nature*
440 *communications* **12**, 1–13 (2021).
- 441 28. Liu, Y.-Y. & Barabási, A.-L. Control principles of complex systems. *Reviews of Modern*
442 *Physics* **88**, 035006 (2016).
- 443 29. Löber, J. *Optimal trajectory tracking of nonlinear dynamical systems* (Springer, 2016).
- 444 30. Lai, S. *et al.* Effect of non-pharmaceutical interventions to contain covid-19 in china. *Nature*
445 **585**, 410–413 (2020).
- 446 31. López, L. & Rodó, X. The end of social confinement and covid-19 re-emergence risk. *Nature*
447 *Human Behaviour* **4**, 746–755 (2020).
- 448 32. COVID, T. I., Reiner, R., Barber, R. & Collins, J. Modeling covid-19 scenarios for the united
449 states. *Nature medicine* (2020).
- 450 33. Keeling, M. J. & Rohani, P. *Modeling infectious diseases in humans and animals* (Princeton
451 University Press, 2011).
- 452 34. Thompson, M. G. *et al.* Interim estimates of vaccine effectiveness of bnt162b2 and mrna-
453 1273 covid-19 vaccines in preventing sars-cov-2 infection among health care personnel, first
454 responders, and other essential and frontline workers (2021).
- 455 35. Stewart, G., Heusden, K. & Dumont, G. How control theory can help us control covid-19.
456 *IEEE Spectrum* **57**, 22–29 (2020).

- 457 36. Gertler, P. J., Martinez, S., Premand, P., Rawlings, L. B. & Vermeersch, C. M. *Impact evalua-*
458 *tion in practice* (The World Bank, 2016).
- 459 37. Dowdle, W. R. The principles of disease elimination and eradication. *Bulletin of the World*
460 *Health Organization* **76**, 22 (1998).
- 461 38. Wang, R. *et al.* Analysis of sars-cov-2 mutations in the united states suggests presence of four
462 substrains and novel variants. *Communications Biology* **4**, 1–14 (2021).
- 463 39. Chowdhury, M. A., Hossain, N., Kashem, M. A., Shahid, M. A. & Alam, A. Immune response
464 in covid-19: A review. *Journal of Infection and Public Health* (2020).
- 465 40. Lee, A., Thornley, S., Morris, A. J. & Sundborn, G. Should countries aim for elimination in
466 the covid-19 pandemic? *bmj* **370** (2020).
- 467 41. Heywood, A. E. & Macintyre, C. R. Elimination of covid-19: what would it look like and is it
468 possible? *The Lancet Infectious Diseases* **20**, 1005–1007 (2020).
- 469 42. Metcalf, C. J. E., Morris, D. H. & Park, S. W. Mathematical models to guide pandemic
470 response. *Science* **369**, 368–369 (2020).
- 471 43. Thompson, R. N. *et al.* Key questions for modelling covid-19 exit strategies. *Proceedings of*
472 *the Royal Society B* **287**, 20201405 (2020).
- 473 44. Covid-19 vaccinations in the united states. [https://covid.cdc.gov/covid-data-](https://covid.cdc.gov/covid-data-tracker/vaccinations)
474 [tracker/vaccinations](https://covid.cdc.gov/covid-data-tracker/vaccinations). Accessed: 2021-03-2.
- 475 45. Baker, M. G., Kvalsvig, A., Verrall, A. J., Telfar-Barnard, L. & Wilson, N. New zealand’s
476 elimination strategy for the covid-19 pandemic and what is required to make it work. *The New*
477 *Zealand Medical Journal (Online)* **133**, 10–14 (2020).
- 478 46. Diekmann, O., Heesterbeek, H. & Britton, T. *Mathematical tools for understanding infectious*
479 *disease dynamics*, vol. 7 (Princeton University Press, 2012).

- 480 47. Oldenburg, B. & Glanz, K. Diffusion of innovations. *Health behavior and health education: Theory, research, and practice* **4**, 313–333 (2008).
- 481
- 482 48. Flaxman, S. *et al.* Estimating the effects of non-pharmaceutical interventions on covid-19 in
483 europe. *Nature* **584**, 257–261 (2020).
- 484 49. Group, W. H. O. W. Nonpharmaceutical interventions for pandemic influenza, national and
485 community measures. *Emerging infectious diseases* **12**, 88 (2006).
- 486 50. Qi, J., Wang, S., Fang, J.-a. & Diagne, M. Control of multi-agent systems with input delay via
487 pde-based method. *Automatica* **106**, 91–100 (2019).
- 488 51. Smyshlyaev, A. & Krstic, M. *Adaptive control of parabolic PDEs* (Princeton University Press,
489 2010).
- 490 52. Agachi, P. S., Cristea, M. V., Csavdari, A. A. & Szilagyi, B. *Model predictive control* (De
491 Gruyter, 2016).
- 492 53. De Silva, C. W. *Intelligent control: fuzzy logic applications* (CRC press, 1995).
- 493 54. Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track covid-19 in real
494 time. *The Lancet infectious diseases* **20**, 533–534 (2020).
- 495 55. Safegraph. <https://covid.cdc.gov/covid-data-tracker/national-lab>. Accessed: 03 20 2021.
- 496 56. Covid-19 public monitor. <https://today.yougov.com/covid-19>. Accessed: 03 20 2021.
- 497 57. Gao, F. & Han, L. Implementing the nelder-mead simplex algorithm with adaptive parameters.
498 *Computational Optimization and Applications* **51**, 259–277 (2012).

499 **Acknowledgements** We thank Bhatiya Rathnayake for fruitful discussions on developing the feedback
500 system and the paper.

501 **Funding** This work was supported in part by the Department of Mechanical Aerospace and Nuclear En-
502 gineering Department at Rensselaer Polytechnic Institute, Troy, NY.

503 **Author Contributions** M.D. and J.G. conceived the project and designed the experiments; Q.W. and L.Z
504 collected the data set and analyzed the data; L.Z., M.D., and J.G. carried out theoretical calculations and
505 performed the experiments; all authors wrote the manuscript.

506 **Competing Interests** The authors declare that they have no competing financial interests.

507 **Data and materials availability** All data needed to evaluate the paper's conclusions are presented in this
508 paper. Derived Data and codes that support the findings of this article are available in
509 https://github.com/lucinezhong/controllers_ode_COVID.git.

510 **Additional information** Supplementary text including Fig. S1-S7, Tab. S1, and Eqs. (S1)-(S12).




Figure 1: The SIRD-model based feedback control system reveals how the interventions' magnitudes and timing govern the dynamics of disease. **a** Based on nonlinear feedback control law, we develop the controllers $U_{\Theta} = [U_{\beta}, U_{\gamma}, U_{\delta}]^T$ working as the edge control on infection rate, recovery rate, and death rate. On the other side, the vaccination V works as the node control on susceptible population. **b** With these controllers, the output trajectory of disease $X = [S, I, R, D]^T$ of the feedback control system fit with the real-world infection data of the disease. **c** Through the model, which includes the nonlinearity or interactions between NPIs, the human behaviour toward NPIs (e.g., stay-at-home order θ_s , face-mask wearing θ_f , and testing θ_g) are linked to the controllers U_{Θ} through their effects (e.g., $w_{\Theta}^s, w_{\Theta}^f, w_{\Theta}^g$).




Figure 2: **The designed feedback controllers U_{Θ} drive the output trajectories (\hat{X}) in the SIRD model ingeniously fits the reported trajectories (\hat{X}_d) for 381 MSAs.** **a** The reported data (dots) of infected/recovered/dead cases are fitted with the output trajectory (solid line) for example MSAs, i.e., "New York" MSA and "Houston" MSA. **b** Comparison between the reported data and output data at all MSAs. Each MSA represent a dot. **c** All MSAs' temporal infection rate, $[\beta_0 + U_{\beta}(t)]$, recovery rate, $[\gamma_0 + U_{\gamma}(t)]$, and death rate, $[\delta_0 + U_{\delta}(t)]$ with marking out the examples MSAs' rates. **d** shows the MSA's temporal effective reproductive ratio (R_e) and **e** shows each MSA's average effective reproductive ratio from 14 February 2020 to 20 February 2021 in the cartogram map, in which geometry of regions are distorted according to their population. The effective reproductive ratio reaches the lowest as of 20 February 2021.




Figure 3: **NPIs selection for predicting the designed controllers U_Θ .** Given eight NPIs, i.e., stay-at-home order, school closure, quarantine, working from home, face-mask wearing, testing, frequent hand wash, and avoid crowding, we test the accuracy of predictive model of Eq. (4) with different combinations of NPIs for U_β (a), U_γ (b), and U_δ (c). The model achieves high parsimony (with fewer NPIs) and high level of goodness of fit (with lowest mean absolute error) using three NPIs, which are stay-at-home order, face-mask wearing, and testing.




Figure 4: The learned effects enable to use magnitude of NPIs to predict infection at each MSA. Using the 70% NPIs and infection data, we learned the NPIs' effects in the model of Eq. (4). Based on the learned effects, **a,b** illustrates of how the magnitude of NPIs determine the controllers ($\hat{U}_\beta(t)$ and $\hat{U}_\delta(t)$) in the example MSAs. To test the accuracy of model, we compare [$\hat{U}_\beta(t)$ and $\hat{U}_\delta(t)$] with analytical controllers [$U_\beta(t)$ and $U_\delta(t)$] with the left 30% NPIs and infection data (vertical shaded area) in the right-side plots of **a,b**. **c** All MSAs' magnitudes of NPIs. The solid line represents the average, and the shaded area represents the standard variance for all MSAs. Though large difference between MSAs' magnitudes of interventions, in **d**, the marginal effects for stay-at-home order and face-mask wearing are mainly negative. Testing, which may helps to find more infection and death, has either negative or positive effect. Thus, by taking the estimated controllers $\hat{U} = [\hat{U}_\beta, \hat{U}_\delta, \hat{U}_\gamma]$ as the input the SIRD model, we find the estimated infection/death assemble with reported infection/death with $R^2 > 0.9$, see the two example dates in **e** and **f**. Fig. S3 shows the estimation accuracy for all others dates. It should be noted that as the \hat{U}_γ keeps constantly proportional to \hat{U}_β (see Fig. S1), there is no need of further exploring \hat{U}_γ .




Figure 5: Needed NPIs to keep effective reproductive ratio $R_e \leq 1$ with difference vaccine coverage. Take the "New York" MSA and "Houston" MSA as the examples; **a,b** show the needed magnitude for NPIs in order to keep $R_e \leq 1$ with zero vaccine coverage. The horizontal slices of the "triangular prism" are the visualization for the needed magnitude of stay-at-home order and face-mask wearing if the magnitude of testing is fixed. **c** When people are full vaccinated at different level (vaccine coverage), how much extents of stay-at-home order and face-mask wearing could be relaxed while keep $R_e = 1$. The magnitude of testing is fixed as each MSA' recent testing capacity. These results demonstrate relaxing interventions need thorough and careful considerations when the ratios of full vaccinated people < 0.6 .




Figure 6: Days needed for reaching "Zero COVID" if the saturation of vaccination coverage are reached within 90 days, 180 days, 270 days, and 360 days. By (1) defining "Zero COVID" as that the disease is eliminated when there are zero new infection for 90 days, (2) defining the day reaching "Zero COVID" as the elimination day, (3) assuming that interventions (i.e., stay-at-home order, face-mask wearing, and testing) keep same as that from 5 January 2021 to 11 February 2021, (4) consider ratio of people full vaccinated as the vaccination coverage, we test the elimination days for MSAs since 12 January 2021. **a** The vaccination adoption model $H(t)$ illustrate how saturation of people full vaccinated is reached in period T_s . Specifically, the orange line is the reported cumulative vaccination coverage. **b** MSAs' estimated elimination days if 50% are full vaccinated with 360 days. **c** Box plots for the elimination days, and the additional death till elimination days for different saturation of vaccination coverage within different time period T_s .